MedTrace Logo

A Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metastatic Colorectal Carcinoma

NCT03096899 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-08-31

No results posted yet for this study

Summary

The primary objective of this study is to estimate overall survival in patients only receiving best supportive care (BSC) for treatment-resistant, metastatic colorectal carcinoma. The primary efficacy outcome is overall survival, defined as the time from the date of the radiographic scan demonstrating disease progression post available treatments (time of origin, T0) to death from any cause.

Conditions

  • Metastatic Colorectal Carcinoma

Interventions

OTHER

Observational

Best Supportive Care

Sponsors & Collaborators

  • The Rogosin Institute

    lead OTHER

Principal Investigators

  • Barry Smith, M.D., Ph.D. · The Rogosin Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-08-22
Completion
2018-08-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096899 on ClinicalTrials.gov